SomaLogic, Citogen partner to expand authorized site program in Europe
- SomaLogic (NASDAQ:SLGC) has announced its collaboration with Citogen, the Longwood Group’s customer services and support unit, to establish the company’s first authorized site in Spain.
- As part of the agreement, Citogen will offer the 7,000-plex SomaScan Assay and provide SomaScan data to their customers in Southern Europe supporting biological research.
- The ability of the SomaScan technology to measure thousands of proteins in a single sample is a powerful tool for advancing the Co.'s understanding of the biology of complex diseases.
- “The Citogen laboratory has the ability to expand the reach of the SomaScan Platform in Europe and we are pleased to be working with this extraordinary research organization to provide their life sciences customers the technology and innovation that will propel their scientific endeavors forward,” said SomaLogic CEO Adam Taich.